Experimental cell therapy targets stubborn autoimmune diseases
NCT ID NCT07333118
Summary
This early-stage study is testing a new cell therapy called GT801 for people with moderate-to-severe autoimmune diseases that haven't responded to standard treatments. The trial will enroll 22 adults with conditions like lupus, scleroderma, or inflammatory muscle diseases to check the safety of different doses and see how the therapy behaves in the body. Researchers will monitor for side effects and look for early signs that the treatment might help control these difficult diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE REFRACTORY AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.